SOUTH JORDAN, Utah, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading
manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures,
particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced that it has completed the acquisition
of Cianna Medical, Inc. headquartered in Aliso Viejo, California, in a merger transaction through which Cianna Medical has become a
wholly-owned subsidiary of Merit.
The purchase consideration was an upfront payment of $135 million in cash with potential earn-out payments of an
additional $15 million for achievement of supply chain and scalability metrics, and up to an additional $50 million for achievement
of sales milestones.
Cianna Medical is a leader in wire-free breast localization and has been focused on breast conservation for 11
years. Cianna Medical develops, manufactures and markets innovative medical products designed to reduce costs, improve
quality and reduce the anxiety and stress breast cancer treatments place on women and their families. Its research,
development and commercialization teams developed the first non-radioactive, wire-free breast localization system and the world’s
only technology that utilizes RADAR in human tissue. Its SCOUT® and SAVI® Brachy technologies are FDA-cleared and address unmet
needs in the delivery of radiation therapy, tumor localization and surgical guidance.
“We are delighted to have Cianna Medical join the Merit family,” said Fred P. Lampropoulos, Merit’s Chairman and
Chief Executive Officer. “We are looking forward to continuing Cianna’s momentum, expanding internationally, and associating
with Cianna Medical’s domestic sales and marketing team.”
2018 GUIDANCE
The effect of the Cianna Medical acquisition on Merit’s earnings for 2018 is expected to be non-accretive to Merit earnings per
share on a GAAP basis in the range of ($0.09-$0.11) per common share and neutral to accretive to Merit earnings per share on a
non-GAAP basis in the range of $0.00–$0.02 per common share, with anticipated GAAP gross margins of 55-65% and non-GAAP gross
margins of 70-75% on the Cianna Medical products, accretive to both Merit’s GAAP gross margin and non-GAAP gross margin in the
range of 10-20 basis points, and add revenues in the range of $5-$7 million. NOTE: Non-GAAP earnings per share accretion and
non-GAAP gross margin are non-GAAP financial measures. Information about how Merit uses non-GAAP measures in its business,
and an explanation of how these measures relate to their most directly comparable GAAP financial measures, is included under the
heading “Non-GAAP Financial Measures” below.
2019 GUIDANCE
The effect of the Cianna Medical acquisition on Merit’s earnings for 2019 is expected to be non-accretive to Merit earnings per
share on a GAAP basis in the range of ($0.06-$0.10) per common share and accretive to Merit earnings per share on a non-GAAP basis
in the range of $0.08–$0.13 per common share, with anticipated GAAP gross margins of 55-65% and non-GAAP gross margins of 70-75% on
the Cianna Medical products, accretive to both Merit’s GAAP gross margin and non-GAAP gross margin in the range of 55-130 basis
points, and add revenues in the range of $50-$56 million. NOTE: Non-GAAP earnings per share accretion and non-GAAP gross
margin are non-GAAP financial measures. Information about how Merit uses non-GAAP measures in its business, and an
explanation of how these measures relate to their most directly comparable GAAP financial measures, is included under the heading
“Non-GAAP Financial Measures” below.
Piper Jaffray & Co. and Raymond James & Associates acted as financial advisors to Merit, and J.P. Morgan
Securities LLC acted as financial advisor to Cianna Medical. Parr Brown Gee & Loveless P.C. served as the legal advisor to
Merit. Wilson Sonsini Goodrich & Rosati, P.C. served as legal advisor to Cianna Medical.
ABOUT MERIT
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable
medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology,
critical care and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and
clinical support team totaling in excess of 300 individuals. Merit employs approximately 5,600 people worldwide with
facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; San Jose and
Aliso Viejo, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico;
Joinville, Brazil; Markham, Ontario, Canada; Melbourne, Australia; Tokyo, Japan; and Singapore.
FORWARD-LOOKING STATEMENTS
Statements contained in this release which are not purely historical, including, without limitation, statements regarding Merit's
forecasted plans, revenues, earnings per share, gross margins or financial results (on a GAAP and non-GAAP basis) or anticipated or
completed acquisitions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
and are subject to risks and uncertainties such as those described in Merit's Annual Report on Form 10-K for the year ended
December 31, 2017 and subsequent filings with the Securities and Exchange Commission. Such risks and uncertainties include the
following: Merit's potential inability to successfully manage the integration of Cianna Medical and achieve anticipated financial
results, product development and other anticipated benefits; uncertainties as to whether Merit will achieve sales, gross margin,
cost of goods sold, cash flow and other results from the Cianna Medical acquisition which are comparable to the experience of
Cianna Medical; unknown costs and risks associated with the business and operations of Cianna Medical, Merit’s internal models or
the projections in this release; governmental scrutiny and regulation of the medical device industry, including governmental
inquiries, investigations and proceedings involving Merit or the business and operations conducted by Cianna Medical; how the
occurrence of any unanticipated event or cost in connection with the integration of Cianna Medical may affect Merit’s projected
ability to comply with debt covenants; infringement of acquired technology or the assertion that acquired technology infringes the
rights of other parties; the potential of fines, penalties or other adverse consequences if Merit's or Cianna Medical’s employees
or agents violate the U.S. Foreign Corrupt Practices Act or other laws or regulations; laws and regulations targeting fraud and
abuse in the healthcare industry; potential for significant adverse changes in governing regulations; changes in tax laws and
regulations in the United States or other countries; increases in the prices of commodity components; negative changes in economic
and industry conditions in the United States or other countries; termination or interruption of relationships with Merit's or
Cianna Medical’s suppliers, or failure of such suppliers to perform; the effects of fluctuations in exchange rates on projected
financial results; development of new products and technology that could render Merit's or Cianna Medical’s products obsolete;
changes in healthcare policies or markets related to healthcare reform initiatives; failure to comply with applicable environmental
laws; changes in key personnel; work stoppage or transportation risks; price and product competition; availability of labor and
materials; fluctuations in and obsolescence of inventory; and other factors referred to in Merit's Annual Report on Form 10-K for
the year ended December 31, 2017 and other materials filed with the Securities and Exchange Commission. All subsequent
forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these
cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates
are subject to change and are not intended to be relied upon as predictions of future operating results, and Merit assumes no
obligation to update or disclose revisions to those estimates.
NON-GAAP FINANCIAL MEASURES
Although Merit’s financial statements are prepared in accordance with accounting principles generally accepted in the United States
of America (“GAAP”), Merit’s management believes that certain non-GAAP financial measures referred to in this release provide
investors with useful information regarding the underlying business trends and performance of Merit’s ongoing operations and can be
useful for period-over-period comparisons of such operations. Non-GAAP financial measures used in this release include:
- non-GAAP gross margin; and
- non-GAAP earnings per share.
Merit’s management team uses these non-GAAP financial measures to evaluate Merit’s profitability and efficiency,
to compare operating results to prior periods, to evaluate changes in the operating results of its operating segments, and to
measure and allocate financial resources internally. However, Merit’s management does not consider such non-GAAP measures in
isolation or as an alternative to such measures determined in accordance with GAAP.
Readers should consider non-GAAP measures used in this release in addition to, not as a substitute for,
financial reporting measures prepared in accordance with GAAP. These non-GAAP financial measures generally exclude some, but not
all, items that may affect Merit's net income. In addition, they are subject to inherent limitations as they reflect the exercise
of judgment by management about which items are excluded. Merit believes it is useful to exclude such items in the calculation of
non-GAAP earnings per share and non-GAAP gross margin because such amounts in any specific period may not directly correlate to the
underlying performance of Merit’s business operations and can vary significantly between periods as a result of factors such as new
acquisitions, non-cash expenses related to amortization of previously acquired tangible and intangible assets, unusual compensation
expenses or expenses resulting from non-ordinary course litigation, governmental proceedings or changes in tax regulations. Merit
may incur similar types of expenses in the future, and the non-GAAP financial information included in this release should not be
viewed as a statement or indication that these types of expenses will not recur. Additionally, the non-GAAP financial measures used
in this release may not be comparable with similarly titled measures of other companies. Merit urges investors and potential
investors to review the explanations below addressing how its non-GAAP financial measures relate to their most directly comparable
GAAP financial measures, and not to rely on any single financial measure to evaluate Merit’s business or results of operations.
Non-GAAP Gross Margin
Non-GAAP gross margin is calculated by reducing GAAP cost of sales by amounts recorded for amortization of intangible assets and
inventory mark-up related to acquisitions.
Non-GAAP Net Income
Non-GAAP net income is calculated by adjusting GAAP net income for certain items which are deemed by Merit’s management to be
outside of core operations and vary in amount and frequency among periods, such as expenses related to new acquisitions, non-cash
expenses related to amortization of acquired tangible and intangible assets, unusual compensation expenses or expenses resulting
from non-ordinary course litigation, governmental proceedings or changes in tax regulations, as well as other items.
Non-GAAP Earnings Per Share
Non-GAAP earnings per share is defined as non-GAAP net income divided by the diluted shares outstanding for the corresponding
period.
Contact: Anne-Marie Wright, Vice President, Corporate Communications
Phone: (801) 208-4167 e-mail: awright@merit.com Fax: (801) 253-1688
